Platinum (Pt) drugs have developed rapidly in clinical applications because of their broad and highly effective antitumor effects. In recent years, with the rapid development of immunotherapy, Pt-based antitumor agents have gained new challenges and opportunities. Since the discovery of their pharmacological effects in immunotherapy and tumor microenvironment regulation, research into Pt drugs has progressed to multi-ligand and multi-functional Pt precursors and their own shortcomings have been further highlighted. With the development of antitumor immunotherapy and the rise of combination therapy, the development of Pt-based drugs has started to move in the direction of multi-targeting, nanocarrier modification, immunotherapy and photodynamic therapy. In this paper, we first overview the recent applications of Pt-based drugs in antitumor inorganic chemistry, with a focus on summarizing the application of Pt-based drugs and their precursors in the anticancer immune response. The paper also provides a reasonable outlook on the future development of Pt-based drugs from the chemical and immunological perspectives, relying on the existing content and problems of Pt-based drug development. On the basis of the gathered information, joint multidisciplinary programs on implementing comprehensive immune analyses for the future development of novel anticancer metal compounds should be initiated.

中文翻译：

---

更老但更强：铂类抗肿瘤药物的开发和肿瘤免疫研究进展

铂（Pt）类药物因其广泛而高效的抗肿瘤作用在临床应用中发展迅速。近年来，随着免疫疗法的快速发展，铂类抗肿瘤药物获得了新的挑战和机遇。自从发现其在免疫治疗和肿瘤微环境调控方面的药理作用以来，铂类药物的研究向多配体、多功能铂前体方向发展，其自身的不足进一步凸显。随着抗肿瘤免疫治疗的发展和联合治疗的兴起，铂基药物的发展开始向多靶点、纳米载体修饰、免疫治疗和光动力治疗方向发展。在本文中，我们首先概述了铂基药物在抗肿瘤无机化学中的近期应用，重点总结了铂基药物及其前体在抗癌免疫反应中的应用。论文还结合Pt基药物开发存在的内容和问题，从化学和免疫学角度对Pt基药物的未来发展提出了合理的展望。在收集到的信息的基础上，应启动实施综合免疫分析的联合多学科计划，以促进新型抗癌金属化合物的未来发展。论文还结合Pt基药物开发存在的内容和问题，从化学和免疫学角度对Pt基药物的未来发展提出了合理的展望。在收集到的信息的基础上，应启动实施综合免疫分析的联合多学科计划，以促进新型抗癌金属化合物的未来发展。论文还结合Pt基药物开发存在的内容和问题，从化学和免疫学角度对Pt基药物的未来发展提出了合理的展望。在收集到的信息的基础上，应启动实施综合免疫分析的联合多学科计划，以促进新型抗癌金属化合物的未来发展。